Previous 10 | Next 10 |
Cancer specialist’s shares have nearly doubled in the last six months after it posted its first-ever profit and named two well-connected board members. I-Mab's shares have nearly doubled over the past six months on the major licensing deal, fundraising, and pending drug approva...
I-Mab Announces Multiple Advancements of 4-1BB Bispecific Antibody Portfolio PR Newswire First patient dosed in U.S. phase 1 clinical trial of TJ-CD4B/ABL111 in patients with advanced or metastatic solid tumors China sites to join the dose expansion part ...
I-Mab Honored with Top Rankings by Institutional Investor PR Newswire SHANGHAI and GAITHERSBURG, Md. , June 30, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and c...
I-Mab Announces Upcoming Participation at July Conference PR Newswire SHANGHAI and GAITHERSBURG, Md. , June 29, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, developme...
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus Erythematosus PR Newswire SHANGHAI and GAITHERSBURG, Md. , June 25, 2021 /PRNewswire/ -- I-Mab (the "Company") (NASDAQ: IMAB), a clinical stage biopharmaceutical company c...
I-Mab (IMAB) announces the appointment of Andrew Zhu to the company's Scientific Advisory Board ((SAB)).Zhu is a Professor of Medicine at Harvard Medical School, Director Emeritus of Liver Cancer Research at Massachusetts General Hospital as well as Chief Scientific Office...
I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory Board PR Newswire SHANGHAI and GAITHERSBURG, Md. , June 21, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical c...
metamorworks/iStock via Getty Images I-Mab ([[IMAB]] +0.7%) has started discussions with advisors and global pharmaceutical companies seeing a collaboration agreement for its experimental cancer therapy, Uliledlimab Bloomberg reports. The potential deal which will involve an upfront...
Healthcare sector and Real Estate Select Sector SPDR ETF (XLRE) gain of 1.92% and 1.88% respectively during the week outpaced S&P 500 gain of +0.40%.Looking at larger stocks (over $2B market capitalization), far and away the sector's top gainer was "meme stock" favorite ...
tonefotografia/iStock via Getty Images China-based biotech company I-Mab ([[IMAB]] -3.9%) has surged ~61.3% so far this year to outperform the broader market. However, a model update following upward revisions to earnings and multiple expansions has prompted Cantor Fitzgerald analyst Louise C...
News, Short Squeeze, Breakout and More Instantly...
I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md. , July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based, global biotech company, announced today that the Board of Directors of the Company has appointed Mr. ...
I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md. , June 6 , 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a U.S.-based, global biotech company, exclusively focused on the development and potential commercial...
I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire I-Mab enters clinical collaboration with Bristol Myers Squibb to evaluate Claudin 18.2 x 4-1BB bispecific anti...